Johnson & Johnson $JNJ Shares Sold by TrueMark Investments LLC

Key Points

• TrueMark Investments LLC reduced its stake in Johnson & Johnson by 18.9%, selling 7,300 shares in the second quarter, and now owns 31,242 shares valued at approximately $4.77 million.
• Johnson & Johnson reported a $2.26 EPS for the latest quarter, with anticipated earnings per share of 10.58 for the current year, alongside a net margin of 27.26% and return on equity of 33.08%.
• The company declared a quarterly dividend of $1.30 per share, which will be paid on December 9th, representing an annualized dividend yield of 2.7% and a payout ratio of 50.19%.

TrueMark Investments LLC decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 18.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 31,242 shares of the company's stock after selling 7,300 shares during the period. TrueMark Investments LLC's holdings in Johnson & Johnson were worth $4,772,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. GFG Capital LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at $35,000. Stone House Investment Management LLC acquired a new position in Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson during the first quarter valued at $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson during the first quarter worth about $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $193.27 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock's fifty day moving average is $180.49 and its two-hundred day moving average is $164.90. The firm has a market capitalization of $465.45 billion, a P/E ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The business had revenue of $24.02 billion for the quarter. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio is 50.19%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a "hold" rating in a research note on Wednesday. Weiss Ratings upgraded Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, October 8th. UBS Group boosted their price target on Johnson & Johnson from $190.00 to $214.00 and gave the stock a "buy" rating in a research report on Tuesday, October 14th. Citigroup raised their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the company a "buy" rating in a report on Wednesday, October 15th. Finally, HSBC upped their target price on shares of Johnson & Johnson from $210.00 to $215.00 and gave the stock a "buy" rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $199.88.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.